|Application ||WB, IHC-P, IHC-F, FC, IP|
|Calculated MW||43653 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein G|
|Immunogen||Recombinant human p53.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Cellular tumor antigen p53, Antigen NY-CO-13, Phosphoprotein p53, Tumor suppressor p53, TP53, P53|
|Target/Specificity||Mouse anti-p53 antibody, clone DO-7 recognizes the human 53kDa p53 tumour suppressor protein, also known as Cellular tumor antigen p53 or Antigen NY-CO-13, encoded by the TP53 gene. p53 is a 393 amino acid protein with an N-terminal transactivation domain, followed by a proline-rich region and a DNA binding domain in the central core region. The C-terminal region contains a tetramirization domain and a terminal regulatory domain (Joergeret al.2010,Baiet al.2006).p53 is intimately involved in a number of signaling pathways controlling cell division, cycling and apoptosis (Hauptet al.2003) and is thus a potent cancer suppressor. In normal cells the level of p53 expression is low but can be induced by DNA damage or other stress signals (Takagiet al.2005). Activation of p53 leads to growth arrest through its interaction with p21, GADD45 and 14-3-3σ, DNA repair and potentially apoptosis through interaction with Bax,Apaf-1,PUMAandNoxA(Thakuret al.2010). p53 is critically regulated by Mdm2 which can trigger p53 degradation by a ubiquitin dependent system (Moll and Petrenko 2003)Mouse anti-p53 antibody, clone DO-7 recognizes an epitope at the N-terminal end of p53 between amino acids 20-25, binding to both wild type and mutant forms. Clone DO-7 is not expected to recognize the multiple isoforms lacking the N-teminal region.|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-p53 (aa20-25) Antibody, clone DO-7 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Vojtesek, B. et al. (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.J. Immunol. Methods 151: 237-24 2. Bonsing, B. A. et al (1997) Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.Cytometry. 28:11-24. 3. Huang, H.Y. et al. (2008) Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation.Clin Cancer Res. 14: 6023-32. 4. Iannone, F. et al. (2005) Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism.Ann Rheum Dis. 64: 217-21. 5. Xinarianos, G. et al. (2002) p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma.Int J Cancer. 101: 248-52. 6. Lin, L.C. et al. (20006) p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy.Surg Oncol. 15: 211-6.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.